In this issue:
AAVS3 gene therapy for haemophilia B
Grade 5 toxicity and responses in phase 1 haematological malignancy trials
Ruxolitinib for inadequately controlled polycythaemia vera without splenomegaly
Recombinant VWF prophylaxis in severe VWD
Obinutuzumab + venetoclax for previously untreated follicular lymphoma
Temsirolimus + lenalidomide for relapsed/refractory lymphoma
Fedratinib for myelofibrosis according to pre-treatment platelet count
Bosutinib vs. imatinib for newly diagnosed chronic-phase CML
Proton pump inhibition for secondary haemochromatosis in hereditary anaemia
Poor survival in AIHA
Please login below to download this issue (PDF)